The longevity tech sector encompasses therapeutics, cellular reprogramming, diagnostics, and preventive health platforms aimed at extending human healthspan. It serves aging populations and consumers seeking proactive wellness, shifting clinical focus from treating individual late-stage diseases to targeting the fundamental biology of aging.
A market report shows the global longevity biotech and epigenetic reprogramming sector expanding to over $27 billion in 2026. Growth is driven by increasing venture capital, genomic research, and rising demand for preventive and personalized anti-aging therapies.
Following the LifeSpan Summit 2026 in Málaga, global leaders and policy experts discuss the societal shifts needed to match increasing life expectancies. The piece emphasizes that extending human lifespan must be coupled with fostering social connections and healthspan improvements.
A large-scale MRI study examining data from over 14,000 adults has established a direct clinical link between sleep duration, quality, and the accumulation of visceral belly fat. Researchers highlight the implications for metabolic health and age-related preventative care.
Rivus Pharmaceuticals announced plans to present preclinical findings on its small-molecule GLP-1 receptor agonist, RV-8451. The upcoming presentation at ObesityWeek 2026 will outline non-human primate and mouse data focusing on metabolic health improvements.
Celularity Inc. and Vesalius Longevity Labs have entered an exclusive manufacturing agreement to produce Peptual peptide APIs in the United States. The partnership expands Celularity's regenerative longevity portfolio and scales U.S. manufacturing infrastructure for peptide supply.
Smart oven company Tovala has announced a partnership with Bryan Johnson's longevity brand Blueprint to launch 'Longevity Meals'. The new line combines strict nutritional longevity standards with automated smart cooking technology.
An update on how artificial intelligence platforms evaluate 'virtual cells' highlights key technical improvements in grading models for longevity research. These computational enhancements help accurately simulate cellular responses to aging interventions.
Longevitix has teamed up with the CEO of the Buck Institute to integrate advanced longevity science into its AI-driven clinical infrastructure. The collaboration aims to scale personalized and preventive medicine by turning complex patient biomarkers into actionable clinical insights.
At the annual Longevity Investors Conference in Gstaad, global founders, scientists, and investors convened to evaluate how longevity science translates from laboratory hypotheses to validated human clinical data.
Regenerative Medical Technology Group announced a new certification program focusing on complementary and adjunctive technologies used in longevity practices. The curriculum covers plasma exchange, peptide medicine, AI diagnostic tools, and photobiomodulation.
Senior FDA officials outlined how therapies targeting the underlying biology of aging might one day reach formal approval during discussions at ARDD 2026. The move signals that regulatory science is increasingly accommodating longevity as a priority framework.
Longeveron Inc. announced it will present its regenerative medicine and cellular therapies at three major longevity and aging investment forums, including ARDD 2026 in Boston. The company aims to highlight clinical developments regarding aging-related frailty.
An opinion piece explores the ethical and scientific challenges of the growing longevity boom and anti-aging biotech. Artificial intelligence is briefly noted as one of several modern technological advancements.
Researchers published a study detailing how the medicinal herb Erigeron breviscapus alleviates cellular senescence and extends lifespan via AMPK-SIRT1 signaling pathways in animal models.
Biotech skincare brand OneSkin has expanded its product line with a denser peptide-powered moisturizer aimed at mature and dry skin. The release bridges advanced longevity science with barrier comfort for consumer healthspan applications.
The 13th Aging Research and Drug Discovery Meeting (ARDD 2026) announced its full program featuring executives from top pharmaceutical companies, FDA regulators, and longevity biotech innovators convening at Harvard University.
An analysis examining how the bottleneck in longevity tech is no longer science or funding, but effective translation into clinical practice and trusted systems for clinicians and patients.
Insilico Medicine published a landmark study in Cell introducing an open AI toolkit—including LongevityBench, Longevity-LLMs, and LongevityClaw—designed to accelerate aging and longevity research worldwide.
Provera Care's family coordination platform Hello Pearl has been chosen for Springboard Enterprises' first-ever cohort dedicated to the longevity economy. The five-month program focuses on women-led startups innovating solutions for an aging demographic.
The August Wellness Index Report highlights the translation of laboratory longevity breakthroughs to patient bedsides. It emphasizes that cell science and clinical standards are becoming essential for scaling healthspan solutions safely.
Headlines surfaced and scored by PortcoMonitor. Get the full, ranked feed + a daily briefing →